In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
California-headquartered company Agilent Technologies is to spend $725 million on doubling its manufacturing capacity of therapeutic nucleic acids. 10 January 2023
Biotechnology
Another chapter in the long-running immunotherapy patent dispute between Bristol Myers Squibb and Gilead Sciences has been written. 10 January 2023
Pharmaceutical
A UK drug discovery company has announced the appointment of a chief scientific officer (CSO). 10 January 2023
Biotechnology
Shares of Novavax closed up 11.25% at $12.26 yesterday after it announced a successor for its president and chief executive Stanley Erck, who plans to retire. 10 January 2023
Biotechnology
California, USA-based biotech TRex Bio closed up 1.7% at $46.71 yesterday, after it announced a multi-year research collaboration and exclusive worldwide license agreement with US pharma major Eli Lilly to develop novel therapies for the treatment of immune-mediated diseases. 10 January 2023
Generics
Drug imports to Russia are ongoing almost in the same volumes as in the past, despite the current situation in Russia, according to recent statements by Viktor Dmitriev, general director of the Association of Russian Pharmaceutical Manufacturers (ARPM) and some independent local analysts in the field of pharmaceuticals. 10 January 2023
Generics
PSK Pharma, a Russian drugmaker that is part of the local Rus Biopharm Group, is looking to become one of the leading pharmaceutical companies in Russia in the coming years to come, achieving this by a significant increase of its output and expansion of its range, reports The Pharma Letter’s local correspondent. 10 January 2023
Biotechnology
German drugmaker Boehringer Ingelheim and privately-held 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop new cancer therapies. 9 January 2023
Biotechnology
Today, US biotech Arrowhead Pharmaceuticals announced positive top-line data from a Phase II placebo-controlled study evaluating an investigational RNAi therapeutic, fazirsiran (TAK-999/ARO-AAT), for the treatment of alpha-1 antitrypsin (AATD) liver disease. 9 January 2023
Pharmaceutical
Greece’s Hellenic Association of Pharmaceutical Companies (SfEE) has come out fighting on the issue of medicine shortages. 9 January 2023
Biotechnology
A gene therapy for hemophilia A has shown positive results after three years of follow up in a major late-stage clinical trial. 9 January 2023
article
German biopharma company CureVac saw its shares rise 24%, to $7.94 on Friday, after it announced positive preliminary data from ongoing Phase I clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. 9 January 2023
Pharmaceutical
Anglo-Irish company Amryt Pharma has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda four years ago. 9 January 2023
Biotechnology
Shares of Voyager Therapeutics were up almost 30% at $9.00 pre-market this morning, as it announced a second lucrative strategic collaboration with Neurocrine Biosciences. 9 January 2023
Pharmaceutical
Privately-held Swiss drugmaker Helsinn today announced the appointment of the firm’s current chief operating officer, Dr Melanie Rolli, as group chief executive (CEO) effective from January 1, 2023. 9 January 2023
Pharmaceutical
French pharma firm Ipsen is to acquire the liver disease specialist Albireo, a company focused on the therapeutic potential of bile-acid modulators. 9 January 2023
Biotechnology
Boston, USA-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announced the completion of an $85 million financing. 9 January 2023
Biotechnology
After an active M&A year in 2022, UK pharma major AstraZeneca kicked off 2023 with an agreement to acquire USA-based clinical stage biotech CinCor Pharma. 9 January 2023
Pharmaceutical
Stalicla, a Swiss company specializing in the identification of specific phenotypes of autism spectrum disorder (ASD), has entered into an exclusive in-licensing agreement with pharma giant Novartis to develop mavoglurant (AFQ056) as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). 9 January 2023
Biotechnology
Shares of US clinical-stage biotech Immunome dipped 1.3% to $4.66 in after-hours trading on Friday, after US pharma major AbbVie revealed that it has agreed a back-loaded partnership and option accord directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine. 9 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze